HOME | CONTACT
NeutraSal® is number one Product for treatment of Oral Mucositis in the U.S.*
NeutraSal® is a prescription supersaturated calcium phosphate rinse that is indicated to treat the painful symptoms associated with oral mucositis, dry mouth, and Sjögren's Syndrome. It is the number one treatment of oral mucositis in the America.*
For more information about NeutraSal® or our other products, click on a specific link or fill out the Contact Form below with your questions or comments.
Benefits of a Supersaturated Calcium Phosphate Rinse in the Oral Cavity in Xerostomic Patients
A supersaturated calcium phosphate rinse (such as NeutraSal©) is one of the most powerful adjuncts in the care and treatment of the symptoms and severities of dry mouth associated with xerostomia.
CASE STUDY: A Siddiqi, MD, San Antonio, TX
Severe OM was prevalent 100% of the time in patients receiving a combination of chemotherapy and radiotherapy, compared with 60% in patients receiving just chemotherapy.
Proven Efficacy of NeutraSal® in Treatment of Oral Mucositis...
The Role of Saliva in Oral Health: Strategies for Prevention and Management of Xerostomia
NeutraSal® Treats Xerostomia Secondary to Sjögren's...
NeutraSal® relieves painful oral mucositis symptoms...
Data supports NeutraSal® as an advanced electrolyte solution indicated for the treatment of oral mucositis and xerostomia. NeutraSal® relieves painful oral mucositis when initiated at the start of chemo or radiotherapy for patients with neck and/or head.
Market Research Supports NeutraSal® Efficacy...
NeutraSal® Pilot Study in Medication-Induced Xerostomia...
Clinical Data Supports NeutraSal® in the Treatment of OM...
* Based on cumulative sales Q1-Q4, 2013. IMS Data and Published Annual Sales.
We are Invado Pharmaceuticals
Invado Pharmaceuticals is a privately-held company with headquarters in Pomona, NY. The founders and advisory board have over 100 years of collective experience in the Pharmaceutical Industry.
MISSION STATEMENT: Improve the lives of patients, families and health care providers by offering high quality, cost effective medical devices and pharmaceuticals, with primary focus on the supportive care side of Oncology.
NeutraSal® received marketing clearance in the United States by the Food and Drug Administration (FDA) in December 2009. Invado Pharmaceuticals has multiple products in the R+D pipeline and is currently in negotiations with marketing partners for commercialization outside the U.S. including the EU and Asia.
For more information, call 866-963-8881.